donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
VNDA Vanda Pharmaceuticals
10.600
-0.140-1.30%
Post Mkt Price
10.60000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-131.73% -93.2993 106.46% 3.3897 106.46% 3.3897 106.79% 4.0232
Receivable Turnover(T)
3.21% 8.5913 -2.3% 8.5974 -2.3% 8.5974 -12.32% 7.7181
Inventory Turnover(T)
5.63% 19.06 15.17% 22.2377 15.17% 22.2377 17.2% 23.2059
Fixed Assets Turnover(T)
17.04% 20.5595 18.94% 19.9171 18.94% 19.9171 22.17% 19.7837
Total Asset Rate(T)
-5.27% 0.4643 -2.3% 0.4767 -2.3% 0.4767 0.45% 0.4898
ROIC
-47.44% 3.633% 28.81% 6.737% 28.81% 6.737% 60.32% 7.137%
ROE
-47.7% 3.727% 28.12% 6.920% 28.12% 6.920% 59.45% 7.338%
ROA
-48.38% 3.152% 28.19% 5.882% 28.19% 5.882% 59.95% 6.254%
FCF to Sales
-7.78% 22.002% 17.65% 23.694% 17.65% 23.694% 20.78% 20.694%
FCF to Net Income
69.24% 324.093% -10.34% 192.031% -10.34% 192.031% -24.15% 162.051%
Efficiency Ratios
ROE 5 Year Average
-- -- 79.05% 9.307% -- -- -- --
ROA 5 Year Average
-- -- 54.71% 8.138% -- -- -- --
Average 5 Years ROIC
-- -- 83.3% 8.961% -- -- -- --
Profitability Ratios TTM
Gross Margin
0.08% 90.510% -0.14% 90.461% -0.14% 90.461% -0.02% 90.383%
Operating Margin
-39.15% 9.074% 42.98% 15.693% 42.98% 15.693% 88.18% 16.391%
Net Margin
-45.51% 6.789% 31.21% 12.339% 31.21% 12.339% 59.23% 12.770%
EBITDA Margin
-36.82% 0.1014% 38.09% 0.1675% 38.09% 0.1675% 76.19% 0.1745%
R & D Expense Ratio
35.6% 30.130% 25.28% 28.050% 25.28% 28.050% 18.58% 26.420%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-19.13% 1.924% -21.49% 1.991% -21.49% 1.991% -19.21% 2.120%
Total Assets to Common Equity
3.48% 120.201% -0.08% 117.599% -0.08% 117.599% 0.36% 117.523%
Debt to Asset Ratio
-15.96% 2.381% -18.46% 2.449% -18.46% 2.449% -15.87% 2.585%
Current Ratio
-20.43% 5.4249 3.58% 6.4271 3.58% 6.4271 1.04% 6.4143
Quick Ratio
-22.6% 5.1318 3.64% 6.2522 3.64% 6.2522 1.27% 6.215
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -20.05% 11.636% -- -- -- --
Revenue CAGR(5Y)
-- -- -26.67% 12.971% -- -- -- --
Net Income CAGR(3Y)
-- -- -- 9.561% -- -- -- --
FCF 1 Year Growth
-- -- 143.45% 27.375% -- -- -- --
FCF CAGR(3Y)
-- -- -- 139.778% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
CEO: Polymeropoulos M.D., Mihael H.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...